<HTML>
<HEAD>
<TITLE>Prepared and Filed by St Ives Financial</TITLE>
<!--IMSstives413642IMS-->
</HEAD>
<body bgcolor="#ffffff">
<page>


<div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"><div style=" border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"><p></p></div></div><BR>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=4>UNITED STATES</font></b></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=4>SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>WASHINGTON, D.C. 20549</font></b></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><b><font SIZE=4>FORM 8-K</font></b></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><font SIZE=2><b>CURRENT
  REPORT</b></font></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><b><font size=2>Pursuant
  to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><b><font size=2>Date
  of Report: June 12, 2006</font></b></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Date
  of earliest event reported)</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:center;'><b><font size=5>eResearchTechnology, Inc.</font></b></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Exact name of Registrant as specified in its charter)</font></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>
<table width="100%" cellspacing=0 cellpadding=0><tr><td width="50">&nbsp;</td><td align=center valign=top width="280"><b><font size=2>Delaware</font></b><br>
<font size=2>(State or other jurisdiction</font><br>
<font size=2>of incorporation)</font><br></td>
<td align=center valign=top width="280"><b><font size=2>0-29100</font></b><br>
<font size=2>(Commission</font><br>
<font size=2>File Number)</font><br></td>
<td align=center valign=top width="280"><b><font size=2>22-3264604</font></b><br>
<font size=2>(I.R.S. Employer</font><br>
<font size=2>Identification No.)</font><br></td><td width="50">&nbsp;</td></tr></table>
<table width="100%" cellspacing=0 cellpadding=0><tr><td width="50">&nbsp;</td><td align=center valign=top width="280"><font size=2>&nbsp;</font><br></td>
<td align=center valign=top width="280"><br></td>
<td align=center valign=top width="280"><br></td><td width="50">&nbsp;</td></tr></table>
<table width="100%" cellspacing=0 cellpadding=0><tr><td width="50">&nbsp;</td>
    <td align=center valign=top width="300"><b><font size=2>30 South 17</font><sup><font size=2>th</font></sup><font size=2>
      Street, Philadelphia, PA </font></b><br>
      <font size=2>(Address of principal executive offices)</font><br>
    </td>
    <td align=center width="240">&nbsp;</td>
    <td align=center valign=top width="300"><b><font size=2>19103</font></b><br>
      <font size=2>(Zip Code)</font></td>
    <td width="50">&nbsp;</td></tr></table>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><b><font size=2>215-972-0420</font></b></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Registrant&#146;s telephone number, including area code)</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </font></p>



<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'> <tr>

    <td width="35" valign=top style='padding:6.0pt 0in 0in 0in;'>
      <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><img src="emptybox.gif" width="12" height="12"></p>
    </td>
        <td valign=top style='padding:6.0pt 0in 0in 0in;'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=2>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> </td> </tr></table>






<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'> <tr>

    <td width="35" valign=top style='padding:6.0pt 0in 0in 0in;'>
      <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><img src="emptybox.gif" width="12" height="12"></p>
    </td>
        <td valign=top style='padding:6.0pt 0in 0in 0in;'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p> </td> </tr></table>






<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'> <tr>

    <td width="35" valign=top style='padding:6.0pt 0in 0in 0in;'>
      <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><img src="emptybox.gif" width="12" height="12"></p>
    </td>
        <td valign=top style='padding:6.0pt 0in 0in 0in;'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p> </td> </tr></table>






<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'> <tr>

    <td width="35" valign=top style='padding:6.0pt 0in 0in 0in;'>
      <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><img src="emptybox.gif" width="12" height="12"></p>
    </td>
        <td valign=top style='padding:6.0pt 0in 0in 0in;'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> </td> </tr></table>



<div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"><div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"><p></p></div></div>

<p align="center"><font size="2" face="serif"></font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><b><font SIZE=2>ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. </font></b></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>On
  June 12, 2006, the Company approved the appointment of Michael J. McKelvey to
  serve as the Company&#146;s President and Chief Executive Officer effective
  on June 23, 2006. Dr.&nbsp;McKelvey will be entitled to an annualized salary
  of $350,000, a signing bonus of $150,000 that will be payable on or before November
  1, 2006, an annualized bonus opportunity of $175,000, an annualized car allowance
  of $12,000 and 150,000 stock options. The bonus opportunity will be earned pursuant
  to Company&#146;s 2006 Bonus Plan, with 50% of the bonus based on the extent
  to which the Company achieves specified revenue targets and the remaining 50%
  based on the extent to which the Company achieves specified net income targets.
  The stock option award will be issued pursuant to the Company&#146;s 2003 Stock
  Option Plan, as amended, priced at fair market value on the date of grant, which
  will be Dr.&nbsp;McKelvey&#146;s start date, and have a 7-year life with 4-year
  vesting in equal installments.</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>Under
  the terms of Dr.&nbsp;McKelvey&#146;s agreement with the Company, either he
  or the Company may terminate his employment with or without cause (as defined
  therein) at any time. In the event that the Company terminates Dr.&nbsp;McKelvey&#146;s
  employment other than for cause, death or disability, the Company is obligated
  to pay him, in a lump sum, one year in salary and prorated bonus and to continue
  his benefits (as defined therein) for one year, subject to benefit plan restrictions.
  In the event of a change of control (as defined in the agreement) of the Company,
  one-third of Dr.&nbsp;McKelvey&#146;s options would become exercisable. Notwithstanding
  the foregoing, upon any change of control after which either (i) Dr.&nbsp;McKelvey
  is terminated other than for cause or (ii) he resigns his employment within
  60 days after the change of control because neither the Company nor the other
  party to the change of control (the &#147;Buyer&#148;) offers him a position
  with comparable responsibilities, authority, location and compensation, then
  the Company would be obligated to pay him, in a lump sum, up to two years in
  salary and prorated bonus and to continue his benefits for up to two years,
  subject to benefit plan restrictions, and all of his options would become exercisable
  in full. Dr.&nbsp;McKelvey has also agreed to a customary nondisclosure covenant
  and a covenant that, during his employment and for a period of one year thereafter,
  Dr.&nbsp;McKelvey will neither compete with the Company nor solicit any customer,
  vendor, supplier or employee to terminate their relationship with the Company.</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>A
  copy of the Company&#146;s press release issued on June 12, 2006 announcing
  Dr.&nbsp;McKelvey&#146;s appointment is filed herewith as Exhibit 99.1.</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>On
  June 12, 2006, the Company also modified the terms of its Management Employment
  Agreement dated May 2, 2006 with Richard A. Baron, the Company&#146;s Executive
  Vice President and Chief Financial Officer. Under the terms of the agreement
  as modified, upon any change of control prior to December 31, 2006 after which
  either (i) Mr.&nbsp;Baron is terminated other than for cause or (ii) he resigns
  his/her employment within 60 days after the change of control because neither
  the Company nor the other party to the change of control (the &#147;Buyer&#148;)
  offers him a position with comparable responsibilities, authority, location
  and compensation, then, in addition to the existing severance obligations under
  the agreement, the Company would be obligated to pay him in a lump sum payment
  his remaining salary for 2006 and his entire 2006 bonus opportunity to the extent
  not previously paid.</font></p>

<p align="center"><font size="2" face="serif"></font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><b><font SIZE=2>ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.</font></b></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>On June 12, 2006, the company gave notice to Joseph Esposito, the Company&#146;s current President and Chief Executive Officer and a director of the Company, that it was terminating the Management Employment Agreement dated February 7, 2006 between the Company and Mr.&nbsp;Esposito effective on September 11, 2006. See Items 1.01 and 5.02 for a discussion of the Company&#146;s appointment of Michael J. McKelvey to succeed Mr.&nbsp;Esposito as President and Chief Executive Officer.</font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>As
  previously disclosed, as a result of such termination, and subject to receipt
  of a customary release from Mr.&nbsp;Esposito and the execution of a mutual
  non-disparagement agreement, Mr.&nbsp;Esposito will be entitled to receive approximately
  $135,700 as his 2006 bonus and a severance payment of $1,160,000, both of which
  will be paid in cash in a lump sum. In addition, Mr.&nbsp;Esposito will be entitled
  to continue receiving benefits for two years, and any options not then exercisable
  will become exercisable in full.</font></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:left;'><b><font SIZE=2>ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.</font></b></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>On June 12, 2006, the Company appointed Michael J. McKelvey to serve as President and Chief Executive Officer of the Company, effective June 23, 2006. Item 1.01 provides information related to his compensation arrangement with the Company. Since 2001, Dr.&nbsp;McKelvey has been employed by PAREXEL International, one of the largest biopharmaceutical outsourcing organizations in the world, where he has served as Corporate Senior Vice President, Clinical Research Services (CRS). He is responsible for the CRS Americas clinical operations in addition to being in charge of the worldwide data management and biostatistics and programming activities for CRS. </font></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size="2">D</font><font size=2>r.&nbsp;McKelvey
  will succeed Joseph Esposito, who will cease to serve as President and Chief
  Executive Officer of the Company on June 23, 2006 and will serve in a limited
  transition capacity until September 11, 2006. Mr.&nbsp;Esposito will also resign
  from the Company&#146;s Board of Directors effective as of June 23, 2006. </font></p>
<p style=' margin-bottom:0pt; margin-top:12pt;text-align:left;'><b><font SIZE=2>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS</font></b></p>
<p style=' margin-bottom:0pt; margin-top:8pt; margin-left:0.36in;text-align:left;'><font size=2>Exhibit
  99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press release dated June 12, 2006 of eResearchTechnology,
  Inc.</font></p>

<p align="center"><font size="2" face="serif"></font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>SIGNATURES</font></b></p>
<p style=' margin-bottom:0pt; margin-top:8pt;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<div align="Center">

<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'> <tr>
        <td width="49%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="2%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="5%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="44%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:8.0pt;margin-bottom:0pt;'><b><font size=2>eResearchTechnology, Inc.</font></b><br> <b><font size=2>(Registrant)</font></b></p> </td> </tr> <tr>
        <td width="49%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><br>
          <font size=2>Date: June 16, 2006</font></p>
      </td>
        <td width="2%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="5%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=2>&nbsp;</font></p> </td>
        <td width="44%" valign=bottom >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=2>&nbsp;</font><br> <font size=2>&nbsp;</font><br> <font size=2>By: /s/ Richard A. Baron</font></p> </td> </tr> <tr>
        <td width="49%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="2%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="5%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="44%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;'><hr noshade width="100%" color="Gray" size="1"> </td> </tr> <tr>
        <td width="49%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="2%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="5%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>
        <td width="44%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;'><font size=2>Richard A. Baron</font><br> <font size=2>Executive Vice President and</font><br> <font size=2>Chief Financial Officer</font></p> </td> </tr></table>
</div>



<p align="center"><font size="2" face="serif"></font></p>
<hr noshade align="center" width="100%" size="2">




</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "p413681-8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18194}]
{"company-data": {"conformed-name": "ERESEARCHTECHNOLOGY INC /DE/", "cik": "0001026650", "assigned-sic": "8734", "irs-number": "223264604", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29100", "film-number": "06910738"}, "business-address": {"street1": "30 SOUTH 17TH STREET", "city": "PHILADELPHIA", "state": "PA", "zip": "19103", "phone": "2159720420"}, "mail-address": {"street1": "30 SOUTH 17TH STREET", "city": "PHILADELPHIA", "state": "PA", "zip": "19102"}, "former-company": {"former-conformed-name": "PREMIER RESEARCH WORLDWIDE LTD", "date-changed": "19961107"}}
Prepared and Filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
  REPORT
Pursuant
  to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
  of Report: June 12, 2006
(Date
  of earliest event reported)
eResearchTechnology, Inc.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
0-29100
(Commission
File Number)
22-3264604
(I.R.S. Employer
Identification No.)
30 South 17
th
Street, Philadelphia, PA
(Address of principal executive offices)
19103
(Zip Code)
215-972-0420
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On
  June 12, 2006, the Company approved the appointment of Michael J. McKelvey to
  serve as the Company's President and Chief Executive Officer effective
  on June 23, 2006. Dr. McKelvey will be entitled to an annualized salary
  of $350,000, a signing bonus of $150,000 that will be payable on or before November
  1, 2006, an annualized bonus opportunity of $175,000, an annualized car allowance
  of $12,000 and 150,000 stock options. The bonus opportunity will be earned pursuant
  to Company's 2006 Bonus Plan, with 50% of the bonus based on the extent
  to which the Company achieves specified revenue targets and the remaining 50%
  based on the extent to which the Company achieves specified net income targets.
  The stock option award will be issued pursuant to the Company's 2003 Stock
  Option Plan, as amended, priced at fair market value on the date of grant, which
  will be Dr. McKelvey's start date, and have a 7-year life with 4-year
  vesting in equal installments.
Under
  the terms of Dr. McKelvey's agreement with the Company, either he
  or the Company may terminate his employment with or without cause (as defined
  therein) at any time. In the event that the Company terminates Dr. McKelvey's
  employment other than for cause, death or disability, the Company is obligated
  to pay him, in a lump sum, one year in salary and prorated bonus and to continue
  his benefits (as defined therein) for one year, subject to benefit plan restrictions.
  In the event of a change of control (as defined in the agreement) of the Company,
  one-third of Dr. McKelvey's options would become exercisable. Notwithstanding
  the foregoing, upon any change of control after which either (i) Dr. McKelvey
  is terminated other than for cause or (ii) he resigns his employment within
  60 days after the change of control because neither the Company nor the other
  party to the change of control (the "Buyer") offers him a position
  with comparable responsibilities, authority, location and compensation, then
  the Company would be obligated to pay him, in a lump sum, up to two years in
  salary and prorated bonus and to continue his benefits for up to two years,
  subject to benefit plan restrictions, and all of his options would become exercisable
  in full. Dr. McKelvey has also agreed to a customary nondisclosure covenant
  and a covenant that, during his employment and for a period of one year thereafter,
  Dr. McKelvey will neither compete with the Company nor solicit any customer,
  vendor, supplier or employee to terminate their relationship with the Company.
A
  copy of the Company's press release issued on June 12, 2006 announcing
  Dr. McKelvey's appointment is filed herewith as Exhibit 99.1.
On
  June 12, 2006, the Company also modified the terms of its Management Employment
  Agreement dated May 2, 2006 with Richard A. Baron, the Company's Executive
  Vice President and Chief Financial Officer. Under the terms of the agreement
  as modified, upon any change of control prior to December 31, 2006 after which
  either (i) Mr. Baron is terminated other than for cause or (ii) he resigns
  his/her employment within 60 days after the change of control because neither
  the Company nor the other party to the change of control (the "Buyer")
  offers him a position with comparable responsibilities, authority, location
  and compensation, then, in addition to the existing severance obligations under
  the agreement, the Company would be obligated to pay him in a lump sum payment
  his remaining salary for 2006 and his entire 2006 bonus opportunity to the extent
  not previously paid.
ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.
On June 12, 2006, the company gave notice to Joseph Esposito, the Company's current President and Chief Executive Officer and a director of the Company, that it was terminating the Management Employment Agreement dated February 7, 2006 between the Company and Mr. Esposito effective on September 11, 2006. See Items 1.01 and 5.02 for a discussion of the Company's appointment of Michael J. McKelvey to succeed Mr. Esposito as President and Chief Executive Officer.
As
  previously disclosed, as a result of such termination, and subject to receipt
  of a customary release from Mr. Esposito and the execution of a mutual
  non-disparagement agreement, Mr. Esposito will be entitled to receive approximately
  $135,700 as his 2006 bonus and a severance payment of $1,160,000, both of which
  will be paid in cash in a lump sum. In addition, Mr. Esposito will be entitled
  to continue receiving benefits for two years, and any options not then exercisable
  will become exercisable in full.
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On June 12, 2006, the Company appointed Michael J. McKelvey to serve as President and Chief Executive Officer of the Company, effective June 23, 2006. Item 1.01 provides information related to his compensation arrangement with the Company. Since 2001, Dr. McKelvey has been employed by PAREXEL International, one of the largest biopharmaceutical outsourcing organizations in the world, where he has served as Corporate Senior Vice President, Clinical Research Services (CRS). He is responsible for the CRS Americas clinical operations in addition to being in charge of the worldwide data management and biostatistics and programming activities for CRS.
D
r. McKelvey
  will succeed Joseph Esposito, who will cease to serve as President and Chief
  Executive Officer of the Company on June 23, 2006 and will serve in a limited
  transition capacity until September 11, 2006. Mr. Esposito will also resign
  from the Company's Board of Directors effective as of June 23, 2006.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit
  99.1     Press release dated June 12, 2006 of eResearchTechnology,
  Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
eResearchTechnology, Inc.
(Registrant)
Date: June 16, 2006
By: /s/ Richard A. Baron
Richard A. Baron
Executive Vice President and
Chief Financial Officer